Currency and pricing squeeze GlaxoSmithKline as new shingles vaccine shines

GlaxoSmithKline's new shingles vaccine Shingrix exceeded expectations in the first quarter, but the drugmaker's sales and earnings fell 2 percent, held back by a stronger pound and more pricing pressure in respiratory medicine.